Evidence map›Paper›PMID 35668715›Full record

ArticlemicroPublication biology2022

Tyrosine catabolites influence SKN-1 signaling in a model of Type I Tyrosinemia.

Talha F Siddiqi, Phillip A Frankino, Andrew Dillin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in microPublication biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Talha F Siddiqi *Howard Hughes Medical Institute University of California, Berkeley, CA 94720.
Phillip A Frankino *Howard Hughes Medical Institute University of California, Berkeley, CA 94720.
Andrew DillinHoward Hughes Medical Institute University of California, Berkeley, CA 94720.
Howard Hughes Medical Institute · USUniversity of California, Berkeley · US

Funding

THE MOLECULAR BASIS OF CELL FUNCTIONT32GM007232 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BILDER, DAVID, UNAL, ELCIN · 1985 to 2022
$36.4M
Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
Neuroendocrine Coordination of Mitochondrial Stress Signaling and ProteostasisR01ES021667 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI DILLIN, ANDREW G · 2012 to 2023
$4.6M
Glial regulation of longevity through a transcellular unfolded protein responseR01AG059566 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI DILLIN, ANDREW G · 2018 to 2022
$2.0M
NIA NIH HHS R01 AG059566NIEHS NIH HHS R01 ES021667NIGMS NIH HHS T32 GM007232NIH HHS P40 OD010440
6 · The paper itself

Abstract

Hereditary Tyrosinemia Type 1 (HT1) is a rare genetic disease that results from mutations of the tyrosine catabolism enzyme fumarylacetoacetate hydrolase (FAH) for which there is currently no cure. HT1 is successfully modeled in the nematode

Identifiers

PMID35668715
PMCPMC9163963
OpenAlexW4285742944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.